ReviewDermatologie (Heidelberg, Germany)2026
[Myiasis: a practical approach].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myiasis refers to the infestation of humans or other vertebrates by dipteran larvae that feed on living or necrotic tissue. It occurs worldwide, particularly in tropical and subtropical regions. Furuncular myiasis presents as a painful, erythematous, furuncle-like nodule with a central breathing pore, often accompanied by serous discharge and a sensation of movement. In Central and South America, it is caused by Dermatobia hominis, whereas in sub-Saharan Africa, Cordylobia anthropophaga is the predominant causative species. While D. hominis transfers its eggs to humans via blood-feeding arthropods, C. anthropophaga is commonly transmitted through contaminated clothing dried outdoors. The larvae develop obligatorily in the subcutaneous tissue; development takes several weeks for Dermatobia and typically 1-2 weeks for Cordylobia. The disease follows a progressive course and does not respond to antibiotic therapy. Treatment consists of mechanical removal of the larva followed by local wound care. Tetanus vaccination status should be assessed and updated if necessary. Antibiotics are indicated only in cases of bacterial superinfection. Migratory myiasis results from the migration of dipteran larvae within the skin and presents with intensely pruritic, serpiginous or linear skin lesions. Important causative agents include Gasterophilus and Hypoderma spp. Treatment consists of complete removal of the larva. Aggressive wound myiasis results from the infestation of open or necrotic wounds as well as skin neoplasms by dipteran larvae. In facultative myiasis, larvae of the family Calliphoridae feed on devitalized and necrotic tissue. This characteristic forms the basis for the therapeutic use of larvae of the species Lucilia in maggot therapy, which is employed for wound debridement in necrotic or fibrin-covered ulcers. In contrast, obligate myiasis can cause tissue destruction, pain, and secondary bacterial infections through damage of viable tissue. Treatment involves complete removal of the larvae, thorough wound cleansing, and debridement. Where clinically indicated, antibiotic therapy may also be required.
Indexed as
Identifiers
42860438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.